{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:09:05Z","timestamp":1750392545575,"version":"3.41.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is characterized by an abnormal thickening of the myocardium, leading to left ventricular outflow tract obstruction. Current treatments for HCM include non\u2013disease-specific medications such as beta blockers or invasive interventions. Mavacamten has been studied for its effects on adenosine triphosphatase, myocardial-specific sarcomeric proteins, and myocardial tissue calcium sensitivity. Given these properties, mavacamten could be used as a disease-specific treatment for HCM. Clinical trials of mavacamten have shown improvements in left ventricular outflow tract obstruction among other favorable improvements in biochemical markers and the clinical symptoms of the disease. While trials to date have been relatively small, mavacamten shows promise as a future disease-specific treatment for HCM.<\/jats:p>","DOI":"10.1097\/crd.0000000000000433","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T20:04:48Z","timestamp":1638561888000},"page":"45-51","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy"],"prefix":"10.1097","volume":"31","author":[{"given":"Michael J.","family":"Capilupi","sequence":"first","affiliation":[{"name":"Department of Medicine, Brown University, Providence, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Cardiology, New York Medical College\/Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11886-020-01381-3","article-title":"Hypertrophic cardiomyopathy 2020.","volume":"22","author":"Kogut","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.jacc.2020.04.017","article-title":"Lessons from MAVERICK-HCM.","volume":"75","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11886-020-1258-x","article-title":"Targeted medical therapies for hypertrophic cardiomyopathy.","volume":"22","author":"Fumagalli","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin.","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"e009627","DOI":"10.1161\/JAHA.118.009627","article-title":"Impact of the myosin modulator mavacamten on force generation and cross-bridge behavior in a murine model of hypercontractility.","volume":"7","author":"Mamidi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin.","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle.","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers.","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","article-title":"Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca 2+ flux caused by thin filament hypertrophic cardiomyopathy mutations.","volume":"318","author":"Sparrow","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1111\/bph.15271","article-title":"Effects of mavacamten on Ca2+ sensitivity of contraction as sarcomere length varied in human myocardium.","volume":"177","author":"Awinda","year":"2020","journal-title":"Br J Pharmacol"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial.","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy.","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy.","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(20)31793-1","article-title":"Mavacamten: treatment aspirations in hypertrophic cardiomyopathy.","volume":"396","author":"Papadakis","year":"2020","journal-title":"Lancet"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:03:02Z","timestamp":1750348982000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000433","relation":{},"ISSN":["1061-5377"],"issn-type":[{"type":"print","value":"1061-5377"}],"subject":[],"published":{"date-parts":[[2022,12,2]]}}}